There are currently 71 active clinical trials seeking participants for Triple Negative Breast Cancer research studies. The states with the highest number of trials for Triple Negative Breast Cancer participants are Texas, California, Florida and New York.
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
NCT06084481
Recruiting
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being developed for the treatment of advanced solid tumors. Study doctors put the participants in groups called cohorts. Each cohort receives ABBV-400 alone (monotherapy) followed by a safety follow-up per... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: City of Hope National Medical Center /ID# 258645, Duarte, California +32 locations
Conditions: Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer, Head and Neck Squamous-Cell Carcinoma
Register for Updates
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
NCT02977468
Recruiting
Assess response to pembrolizumab in both primary tumor, normal breast stroma, circulating lymphocytes and serum exosomes in treatment naive triple negative breast cancer (TNBC) patients. Assess for change in tumor-infiltrating lymphocytes (TILS) both stromal (sTILS) and intraepithelial (iTILS) in newly diagnosed early stage TNBC patients treated with two doses of MK-3475 prior to lumpectomy.
Gender:
Female
Ages:
Between 21 years and 80 years
Trial Updated:
06/17/2024
Locations: Emory University, Atlanta, Georgia +2 locations
Conditions: Triple Negative Breast Cancer
Register for Updates
Comparison of the Breast Tumor Microenvironment
NCT03165487
Recruiting
The goal of the project is to identify a molecular signature of tumor stroma from "normal" adjacent breast tissue obtained prospectively at the time of breast conserving surgery before and after receiving intraoperative radiation therapy (IORT) in subjects that have luminal A and triple negative breast cancer. IORT is considered as being standard of care.
Gender:
Female
Ages:
50 years and above
Trial Updated:
06/17/2024
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Triple Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast
Register for Updates
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC
NCT06351332
Recruiting
This research is being done to evaluate the safety and effectiveness of a drug currently known as Azenosertib (ZN-C3) in combination with the drugs carboplatin and pembrolizumab in metastatic triple-negative breast cancer. The names of the study drugs involved in this study are: Azenosertib (a type of WEE1 inhibitor) Carboplatin (a type of platinum compound) Pembrolizumab (a type of monoclonal antibody)
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Breast Cancer, Breast Cancer Female, Triple Negative Breast Cancer, Hormone Receptor Negative Malignant Tumor Breast Triple, HER2-negative Breast Cancer
Register for Updates
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT06238479
Recruiting
The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +7 locations
Conditions: Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
Register for Updates
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumor... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Alaska Oncology and Hematology, Anchorage, Alaska +507 locations
Conditions: Triple Negative Breast Cancer, PD-L1 Negative
Register for Updates
Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers
NCT05846789
Recruiting
This is a randomized Phase II study of carboplatin monotherapy vs. carboplatin combined with tocilizumab in in Black and non-Black patients with metastatic triple negative or ER low breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/06/2024
Locations: IU Health Joe and Shelly Schwarz Cancer Center, Carmel, Indiana +2 locations
Conditions: Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-low Breast Cancer
Register for Updates
Cardiac Outcomes With Near-Complete Estrogen Deprivation
NCT05309655
Recruiting
The purpose of this research study is to understand what effect near complete estrogen deprivation (NCED) therapy has on the heart in breast cancer patients. Investigators want to understand if NCED changes how the heart works.
Gender:
Female
Ages:
Between 18 years and 55 years
Trial Updated:
06/06/2024
Locations: Duke Cancer Center, Durham, North Carolina +2 locations
Conditions: Breast Cancer, Triple Negative Breast Cancer, Cardiovascular Complications
Register for Updates
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
NCT06451497
Recruiting
This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Pembrolizumab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +2 locations
Conditions: Non Small Cell Lung Cancer, Esophageal Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer, Prostate Cancer, Urothelial Carcinoma, Colorectal Cancer, Triple Negative Breast Cancer, High Grade Ovarian Serous Adenocarcinoma, Diffuse Large B Cell Lymphoma
Register for Updates
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
NCT06264921
Recruiting
The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) to determine the maximum tolerated dose (MTD) and/or preliminary recommended dose for expansion (RDE) of NKT3447 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and the preliminary antitumor activity of NKT3447 in adult subjects with cyclin E1 (CCNE1) amplified ovarian... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: Sarah Cannon Research Institute at HealthONE, Denver, Colorado +4 locations
Conditions: Solid Tumor, Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Tumor, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Metastatic Ovarian Carcinoma, Endometrial Cancer, Endometrial Neoplasms, Endometrial Diseases, Metastatic Endometrial Cancer, Metastatic Endometrial Carcinoma, Advanced Endometrial Carcinoma, Advanced Ovarian Carcinoma, Gastric Cancer, Advanced Gastric Carcinoma, Metastatic Gastric Cancer, Metastatic Gastric Carcinoma, Small-cell Lung Cancer, Small Cell Lung Carcinoma, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, CCNE1 Amplification, Hormone Receptor Negative Breast Carcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Progesterone-receptor-positive Breast Cancer
Register for Updates
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
NCT05848739
Recruiting
This is an open-label, two-part, phase 1-2 study designed to determine the safety, tolerability, PK, pharmacodynamics (PD), and proof-of-concept efficacy of ST316 administered IV in subjects with selected advanced solid tumors likely to harbor abnormalities of the WNT/β-catenin signaling pathway. The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: USC Norris Comprehensive Cancer Center, Los Angeles, California +4 locations
Conditions: Breast Cancer Metastatic, Pancreatic Cancer, NSCLC, Metastatic, Synovial Sarcoma, Colon Cancer, Metastatic Colon Cancer, Melanoma Recurrent, Metastatic Skin Cancer, Melanoma Stage IV, Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Cholangiocarcinoma, Ovarian Cancer, Metastatic Melanoma, Hepatocellular Carcinoma
Register for Updates
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
NCT06318897
Recruiting
To look at the effectiveness of the combination of pembrolizumab, carboplatin, and paclitaxel in participants with stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/30/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Stage 1 cT1b-T1cN0M0, Triple Negative Breast Cancer
Register for Updates